Last reviewed · How we verify
NCT05133479: LK!2
Let's Know!2: Language-focused Intervention for Children at Risk of Comprehension Difficulties
NA trial testing Let's Know! small-group or TierL 2 Intervention in Language Disorders in Children in 241 participants. Participants enrolled and being followed up; not accepting new ones.
30 June 2026
Quick facts
| Lead sponsor | MGH Institute of Health Professions |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 241 |
| Start date | 1 January 2021 |
| Primary completion | 30 June 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Let's Know! small-group or TierL 2 Intervention
Conditions studied
- Language Disorders in Children — all drugs for Language Disorders in Children →
Sponsor
MGH Institute of Health Professions
Who can join
Adults 5 to 12, any sex, with Language Disorders in Children. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In the proposed project, the investigators will conduct a multisite randomized controlled trial (RCT) to determine the efficacy of Let's Know!2, a small-group, language focused comprehension intervention, on children's lower- and higher-level language skills and comprehension skills in the short- and long-term (Specific Aims 1 and 2). The investigators will also explore whether intervention effects are moderated by dosage, initial language skill, developmental language disorder (DLD) status, word reading skill, nonverbal IQ, and family socioeconomic status (Specific Aim 3). Children who have low language skills and are thus at risk for reading comprehension difficulties will participate in the study. Children will be randomly assigned to receive Let's Know! in small groups at their respective schools or to a business-as-usual control condition. The investigators will measure children's language and comprehension skills at the beginning and end of Grade 1 as well as in Grade 2 and Grade 3. The investigators hypothesize that children who experience Let's Know! will end Grade 1 with higher language skills than children in the control condition and that this will translate into better listening and reading comprehension skills as these children matriculate through elementary school.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05133479
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Language Disorders in Children
Currently open trials in the same condition.
- NCT07529327 — Prevent Language Delays and Disorders Among Children of Caregivers With Substance Use Disorders With Community Groups an · NA · recruiting
- NCT07369960 — Repetitive Transcranial Magnetic Stimulation Combined With Language Training for Language Disorders in Children With Glo · NA · recruiting
- NCT05900180 — Pediatric Speech Therapy Session Frequency and Speech Outcomes · NA · active not recruiting
Other MGH Institute of Health Professions trials
Trials by the same sponsor.
- NCT07489053 — Optimizing Functional Recovery After Breast Cancer Treatment · NA · not yet recruiting
- NCT07349030 — Fall Risk Intervention for Stroke · NA · not yet recruiting
- NCT06494423 — Employment Support After Hematopoietic Stem Cell Transplantation · NA · recruiting
- NCT05066178 — Speech Treatment for Minimally Verbal Children With ASD and CAS · NA · recruiting
- NCT06304207 — Telehealth and Onsite Maintenance Exercise in Chronic Lung Disease · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05133479 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by MGH Institute of Health Professions
- Last refreshed: 24 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05133479.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing